Skip to content

Phase II Clinical Trial of 20-Valent Pneumococcal Polysaccharide Conjugate Vaccine

Phase II Clinical Trial of 20-Valent Pneumococcal Polysaccharide Conjugate Vaccine

Status
Active, not recruiting
Phases
Phase 2
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2500097409
Enrollment
Unknown
Registered
2025-02-19
Start date
2025-03-24
Completion date
Unknown
Last updated
2025-02-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Pneumococcal Disease, PD

Interventions

Trial group:Trial vaccination
Control group:Control vaccination

Sponsors

Hubei Provincial Center for Disease Control and Prevention
Lead Sponsor

Eligibility

Sex/Gender
All
Age
No minimum to 5 Years

Inclusion criteria

Inclusion criteria: 1. Permanent healthy people aged 2~5 years, 12~23 months, 7~11 months or 2 months; 2. Obtain the consent of the volunteer's legal guardian and sign the informed consent form; 3. The legal guardian of the volunteer can comply with the requirements of the clinical trial protocol; 4. Armpit body temperature <=37.0°C.

Exclusion criteria

Exclusion criteria: 1. Those with a history of pneumococcal polysaccharide vaccine or pneumococcal conjugate vaccination; 2. Have a history of allergies and asthma, including a history of allergy to vaccines or vaccine ingredients, or have had serious adverse reactions to previous vaccinations, such as allergies, urticaria, dyspnea, angioedema or abdominal pain, etc.; 3. Premature infants (delivered before the 37th week of pregnancy), low birth weight infants (weight at birth =38.0°C) in the past 3 days; 15. Is participating in other drug clinical trials or plans to participate in other drug clinical trials during the trial period; 16. Subject has any other factors that are not suitable for participation in the clinical trial, as judged by the investigator.

Design outcomes

Primary

MeasureTime frame
Positive rate of IgG antibodies against various types of pneumococcal bacteria 30 days after basic immunization;Geometric mean concentration (GMC) of IgG antibodies against various types of pneumococcal bacteria 30 days after basic immunization;

Secondary

MeasureTime frame
Adverse event;Positive rates of IgG antibodies against various types of pneumococcal bacteria 30 days after booster immunization;Geometric mean concentration (GMC) of IgG antibodies against various types of pneumococcal bacteria 30 days after booster immunization;

Countries

China

Contacts

Public ContactYeqing Tong

Hubei Provincial Center for Disease Control and Prevention

63382251@qq.com+86 13971078410

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026